<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04040231</url>
  </required_header>
  <id_info>
    <org_study_id>17-654</org_study_id>
    <nct_id>NCT04040231</nct_id>
  </id_info>
  <brief_title>Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma</brief_title>
  <official_title>Combining a WT1 Cancer Vaccine (Galinpepimut-S) With Checkpoint Inhibition (Nivolumab) in Patients With WT1-Expressing Malignant Pleural Mesothelioma: A Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether it is safe to give Galinpepimut-S and Nivolumab
      together in patients with mesothelioma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 24, 2019</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>up to 24 months</time_frame>
    <description>A dose will be considered tolerable if there are no more than 2 out of 10 participants with dose limiting toxicities.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Mesothelioma</condition>
  <condition>Pleural Mesothelioma</condition>
  <condition>Wilms Tumor</condition>
  <arm_group>
    <arm_group_label>Malignant Pleural Mesothelioma (MPM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with previously treated Malignant Pleural Mesothelioma/MPM</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Galinpepimut-S</intervention_name>
    <description>Galinpepimut-S will be administered alone on weeks 0 and 2. Participants will receive the galinpepimut-S vaccine and nivolumab over 16 weeks in the initial treatment phase.</description>
    <arm_group_label>Malignant Pleural Mesothelioma (MPM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Participants will receive nivolumab and the galinpepimut-S vaccine over 16 weeks in the initial treatment phase.</description>
    <arm_group_label>Malignant Pleural Mesothelioma (MPM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sargramostim</intervention_name>
    <description>All participants will receive Sargramostim (GM-CSF) 70 mcg injected subcutaneously on days 0 and -2 of each cycle</description>
    <arm_group_label>Malignant Pleural Mesothelioma (MPM)</arm_group_label>
    <other_name>GM-CSF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;/= 18 years

          -  Karnofsky performance status &gt;/= 70%

          -  Pathologic diagnosis of malignant pleural mesothelioma at MSK

          -  Positive immunohistochemical staining for WT-1

          -  Patients must have received at least one prior course of pemetrexed-based chemotherapy

          -  Patients of childbearing potential must have a negative serum pregnancy test within 24
             hours of receiving the first treatment on the study (if female) and must be practicing
             an effective form of birth control for the entire duration of treatment (both females
             and males)

          -  Adequate archival or fresh tissue for correlative analyses within 60 days prior to
             starting treatment as long as there was no interval cancer-directed therapy

          -  If sufficient archival or fresh tissue is not available, then a repeat biopsy at
             baseline prior to starting study treatment will be required

          -  Has received and progressed or are refractory to pemetrexed based chemotherapy

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Prior receipt of checkpoint inhibition

          -  Patients with known active hepatitis B or known active hepatitis C virus

          -  Patients with a serious unstable medical illness or another active cancer

          -  Patients with known history of testing positive for human immunodeficiency virus (HIV)
             or known acquired immunodeficiency syndrome (AIDS)

          -  Autoimmune disease requiring treatment with systemic steroids in the past 2 years

          -  Current use of systemic corticosteroids at doses greater than prednisone 10 mg daily
             or the equivalent

          -  Patients with active pneumonitis

          -  Hematologic parameters: Absolute neutrophil count &gt;/= 1000/mcL

          -  Biochemical parameters: Total bilirubin &lt;/= 1.5 mg/dl, AST and ALT &lt;/= 3.0 x upper
             limits of normal, Creatinine &lt;/= 1.5 x upper limits of normal

          -  Platelet count &lt;100,000
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marjorie Zauderer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marjorie Zauderer, MD</last_name>
    <phone>646-888-4656</phone>
    <email>zauderem@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>W. Victoria Lai, MD</last_name>
    <phone>646-449-1983</phone>
    <email>laiw@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjorie Zauderer, MD</last_name>
      <phone>646-888-4656</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjorie Zauderer, MD</last_name>
      <phone>646-888-4656</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center @ Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjorie Zauderer, MD</last_name>
      <phone>646-888-4656</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjorie Zauderer, MD</last_name>
      <phone>646-888-4656</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan - Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjorie Zauderer, MD</last_name>
      <phone>646-888-4656</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjorie Zauderer, MD</last_name>
      <phone>646-888-4656</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 29, 2019</study_first_submitted>
  <study_first_submitted_qc>July 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2019</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mesothelioma</keyword>
  <keyword>Pleural Mesothelioma</keyword>
  <keyword>Wilms Tumor Protein 1</keyword>
  <keyword>WT1</keyword>
  <keyword>galinpepimut-S</keyword>
  <keyword>Montanide</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Phase I</keyword>
  <keyword>17-654</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Wilms Tumor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>• Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

